|
|
 |
|
|
 |
 |
 |
    |
 |
|
 |
Active Investments and Selected Previous Investments
Aileron Therapeutics, Inc. Aileron is developing a technology termed Stapled Peptides, in which short peptide sequences corresponding to an alpha-helix of a protein are stabilized using a synthetic bridge. The corresponding 'stapled' peptides exhibit unique properties that make them particularly suitable as drugs targeting intracellular protein-protein interactions.
Avid Radiopharmaceuticals Avid Radiopharmaceuticals is a clinical-stage product-focused molecular imaging company with significant expertise and intellectual property in the field of molecular brain imaging. Avid has developed proprietary targeting agents to image amyloid plaques and is currently testing these compounds in Phase 3 clinical trials for the diagnosis of Alzheimer's disease. The Avid team is also developing novel agents targeted to the vesicular monoamine transporter (VMAT-2) to image pathology in dementia with Lewy bodies, Parkinson's disease, and has recently started a research project in diabetes mellitus. These agents have the potential to revolutionize early diagnosis and monitoring of disease.
Cabrellis Pharmaceuticals (acquired by Pharmion Corporation) Cabrellis Pharmaceuticals is an oncology company whose primary focus is developing Calsed™, a third generation synthetic anthracycline drug currently approved and commercialized for small-cell and non-small-cell lung cancers in Japan. Cabrellis holds the exclusive North American and European development and commercialization rights to this drug. Cabrellis was developing Calsed™ for small-cell lung cancer and other solid tumors when it was sold to Pharmion Corporation (now Celegene).
CGI Pharmaceuticals CGI Pharmaceuticals is dedicated to the discovery and development of breakthrough small molecule kinase inhibitors for a broad range of oncology/angiogenesis and autoimmune/allergic/inflammatory disease indications. The Company’s fully integrated drug discovery infrastructure comprises proprietary discovery biology, chemistry, and informatics; extensive lead generation and optimization capabilities; and preclinical and clinical development expertise. CGI has successfully identified quality kinase inhibitor lead candidates in three promising drug development programs.
Conforma Therapeutics (acquired by Biogen Idec, BIIB: NASDAQ) Conforma Therapeutics was focused on the design and development of novel drugs for the selective treatment of cancer. Conforma developed drugs that target the cellular HSP90 family of molecular "chaperones" that control protein shape or conformation, including that of key signaling molecules involved in the growth and survival of tumor cells. Conforma was acquired by Biogen-IDEC.
Cylene Pharmaceuticals Cylene Pharmaceuticals is a clinical-stage biotech pharmaceutical company focused on the discovery, development and commercialization of targeted small-molecule drugs to treat life-threatening cancers. Cylene has created a diverse portfolio of product candidates using its two internal proprietary discovery platforms. One of these discovery platforms involves designing novel Nucleolus Targeting Agents (NTAs), and the second discovery platform involves creating first-in-class Serine/Threonine protein kinase inhibitors. Cylene has a Phase II cancer agent derived from the nucleolus targeting technology being studied in carcinoid/neuroendocrine tumors. Additionally, Cylene has several pre-clinical NTA programs. The lead molecule from the Serine/Threonine kinase inhibitor program is an oral inhibitor of protein kinase CK2 which plays important roles within the nucleolus and is currently in early clinical trials.
GlobeImmune GlobeImmune is a biopharmaceutical company pioneering the discovery, development and manufacturing of targeted molecular immunotherapies called Tarmogens® for the treatment of cancer and infectious diseases. Tarmogens (Targeted Molecular Immunogens) are whole, heat-killed recombinant Saccharomyces cerevisiae yeast genetically modified to express one or more protein targets that stimulate the immune system against diseased cells. The whole heat-killed yeast, with the antigen expressed inside, is the product that is administered to the patient. Tarmogens program the cytotoxic T cells (a.k.a. killer T cells) in the patient's immune system to eliminate diseased cells containing the expressed antigen(s). GlobeImmune's patented Tarmogen platform has a number of advantages over existing approaches because Tarmogens generate a potent T cell response, are not neutralized by the host immune system upon repeated administration, do not require a custom vaccine approach and are simple to manufacture.
HemaQuest Pharmaceuticals HemaQuest Pharmaceuticals is a clinical stage company developing small molecule therapeutics based on its short chain fatty acid derivative (SCFAD) technologies to treat anemias and other blood disorders. The Company's initial focus is on the two most common inherited blood disorders, thalassemia and sickle cell anemia. The Company is also developing SCFADs to treat other hematological disorders such as other kinds of anemia and neutropenia.
Hydra Biosciences Hydra Biosciences develops novel drugs to treat pain, inflammation, cardiovascular and other diseases using its expertise in novel ion channels. Hydra's proprietary high throughput screening platforms enable the company to identify and develop drug candidates that address significant unmet medical needs. Hydra's intellectual property portfolio, significant ion channel expertise, and flexible screening systems set it apart from other biopharmaceutical companies. Unlike classical sodium, calcium or potassium voltage-gated channels, Hydra's novel collection of ion channels provides the potential to develop selective and safer ion channel drugs.
InnoCentive InnoCentive is the leading online forum that allows world-class scientists and science-based companies to collaborate in a global scientific community to achieve innovative solutions to complex challenges. Companies including Dow AgroSciences, Eli Lilly and Company, Procter & Gamble and others, which collectively spend billions of dollars on R&D, post scientific problems confidentially on the InnoCentive web site where nearly 100,000 scientists and scientific organizations in more than 175 countries can solve them.
Protagonist Therapeutics Protagonist is a biotechnology company developing novel therapeutics for inflammatory and metabolic conditions by discovering small molecules and constrained peptides that mimic or inhibit interactions between proteins. The company’s discovery platform is a combination of innovative drug design capabilities and synthetic chemistry that is the source of its novel and proprietary pipeline of potential medicines. Protagonist’s research and development programs are focused on addressing some of the world’s most critical health care needs, such as asthma, rheumatoid arthritis, gastro-intestinal disorders and diabetes-related conditions.
Serenex (acquired by Pfizer, Inc., PFE:NYSE) Serenex is an integrated oncology-focused drug discovery and development company whose pipeline includes SNX-5542 orally available small molecule inhibitor of Heat Shock Protein 90 (Hsp90). Hsp90 is an important chaperone protein that regulates the folding and degradation of client proteins that play key roles in oncology, inflammatory diseases, fungal infection resistance, viruses and neurodegenerative diseases such as Alzheimer's. Serenex used its proprietary chemo-proteomics platform to build its internal development pipeline. SNX-5542 was in Phase 1 clinical trials when the company was acquired by Pfizer Pharmaceuticals.
Trinity Biosystems Trinity Biosystems is focused on the design of orally delivered bio-therapeutic macromolecules. Their technology works cooperatively with the natural physiology of the body by taking advantage of a normal receptor-mediated biological process by which large molecules are transported across mucous membranes. Trinity's proprietary platform is called the TriPex™ system. The TriPex™ system utilizes a specific and efficient natural biological transport mechanism: a receptor-mediated transcellular pathway that allows large molecules to enter the body. This pathway allows passage of Trinity's proprietary fusion proteins through the mucosal epithelium and delivery of the therapeutic payload into the blood. The main value of the TriPex™ system is its ability to overcome the absorption barrier, allowing efficient absorption of intact molecule from the intestine and delivery to target tissue.
Viamet Viamet Pharmaceuticals discovers and develops best-in-class inhibitors of validated Metalloenzymes via an innovative and proprietary metal-binding approach. Viamet's Metallophile™ technology is based on its world-class expertise in bioinorganic chemistry and metalloenzymes and allows them to identify validated targets with high therapeutic and commercial potential; leverage existing metalloenzyme inhibitors as the basis for Viamet's best-in-class analogs; and rapidly and cost-effectively generate best-in-class, patentable, small molecule compounds by optimizing the metal-binding component of existing inhibitors. The Metallophile™ Technology has enabled Viamet to efficiently build a portfolio of proprietary drug candidates and leads which represent blockbuster potential. Viamet’s current focus is in the fields of infectious disease and oncology.
XenoPort (XNPT: NASDAQ) XenoPort is a biopharmaceutical company focused on harnessing the body's intrinsic transport systems to improve the oral absorption, distribution and pharmacokinetics of drugs. XenoPort is developing internally discovered product candidates for central nervous disorders and gastroesophageal reflux disease. The company applies an integrated technology platform, consisting of transporter genomics, assay technology, and proprietary chemistries, to engineer drug molecules for active transport.
|
|
|
Copyright © 2009 Eli Lilly and Company. All rights reserved. Privacy Statement |
